What is Regeneron's primary business focus as of year-end 2001?

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and intending to commercialize therapeutic drugs for serious medical conditions. Their core strategy involves leveraging their scientific and technological platforms to build an integrated biopharmaceutical company, while retaining significant ownership and commercialization rights to their pipeline.

What are Regeneron's key product candidates in clinical development?

As of year-end 2001, Regeneron's leading independent programs include AXOKINE® for obesity (in Phase III trials), Pegylated AXOKINE (in preclinical development), IL1 Trap for rheumatoid arthritis (reporting positive Phase I results), IL4/IL13 Trap for asthma/allergic disorders (expected to enter Phase I trials), and VEGF Trap for cancer (in Phase I trials).

How is Regeneron financing its extensive research and development efforts?

Regeneron finances its operations primarily through equity offerings (public and private), debt issuances (convertible senior subordinated notes), revenue from collaboration agreements (e.g., with Procter & Gamble, Amgen), and investment income. Despite significant net losses, the company maintained substantial cash reserves by the end of 2001.

What are the main risks and uncertainties facing Regeneron?

Key risks include the inherent uncertainties in drug development, such as the potential failure of research programs or clinical trials to demonstrate safety and efficacy. Other risks include delays in regulatory approvals, competition from other pharmaceutical companies, reliance on collaborative partners, and the need to obtain and maintain intellectual property rights. The company also notes that patients treated with AXOKINE have developed antibodies, and the long-term implications are still being monitored.

REGN 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed its 2001 10-K on March 21, 2002. The company, a biopharmaceutical firm focused on discovering, developing, and commercializing therapeutic drugs, reported a significant increase in its net loss for 2001 to $76.2 million from $23.2 million in 2000, primarily due to a substantial rise in research and development expenses. This increase in R&D spending was driven by expanded activities in preclinical and clinical development programs, including the initiation of a Phase III clinical program for AXOKINE® for obesity and a Phase I study for IL1 Trap for rheumatoid arthritis. Despite the growing losses, the company maintained a strong liquidity position, ending 2001 with $438.4 million in cash, cash equivalents, and marketable securities, bolstered by successful public and private offerings of its stock and debt during the year. Regeneron continues to advance a diverse pipeline of product candidates, including AXOKINE for obesity and the IL1 Trap and IL4/IL13 Traps for inflammatory and allergic diseases, with several programs in various stages of clinical development.

Key Highlights

1Regeneron's net loss widened significantly in 2001 to $76.2 million, compared to $23.2 million in 2000, primarily driven by increased R&D investment.

2Research and development expenses surged to $91.5 million in 2001, representing 85% of total operating expenses, up from $60.6 million (72% of total) in 2000.

3The company successfully raised substantial capital through stock offerings in March/April 2001 ($153.6M net) and a private placement of convertible senior subordinated notes in October 2001 ($192.7M net), ending the year with $438.4 million in liquid assets.

4AXOKINE®, a potential treatment for obesity, advanced into Phase III clinical trials, with enrollment completed for a pivotal trial involving approximately 2,000 patients.

5Positive preliminary results were reported for the IL1 Trap in Phase I trials for rheumatoid arthritis, showing dose-dependent improvements in disease activity.

6The company is actively developing multiple 'Trap' technologies targeting cytokines (IL1, IL4/IL13) and VEGF, aiming to address inflammatory diseases, asthma, allergies, and cancer.

7Revenue generation remains limited to contract research, development, and manufacturing, with no sales from commercialized product candidates reported.

REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2001

Summary

Key Highlights

Frequently Asked Questions